Clinical trial · no report yet · Phase 2
AMIGO-1
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
- NCT05299125 ↗
- Completed
- Latin American Cooperative Oncology Group
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR Mutations
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Non-small Cell Lung Cancers
- Interventions
- Amivantamab; Lazertinib; Pemetrexed 500 mg
- Arms
- Single Arm: Therapy consisting of lazertinib plus amivantamab plus chemotherapy · Experimental
- Enrollment
- 54
- Primary outcomes
- To evaluate the 18-month progression-free survival (PFS) rate
- Sponsor
- Latin American Cooperative Oncology Group with Janssen, LP
- Start
- May 24, 2023
- Primary completion
- Aug 19, 2024
- Results posted
- No
- Registry record
- NCT05299125 · updated Aug 28, 2026